![\"\"](\"https:\/\/platoai.gbaglobal.org\/wp-content\/uploads\/2023\/12\/cirm-reveals-appointment-of-interim-ceo.jpg\")
<\/p>\n<\/p>\n
CIRM Reveals Appointment of Interim CEO<\/p>\n
The California Institute for Regenerative Medicine (CIRM) has recently announced the appointment of Dr. Maria T. Millan as its interim CEO. This decision comes after the departure of the previous CEO, Dr. C. Randal Mills, who served in the position for nearly seven years.<\/p>\n
Dr. Millan brings a wealth of experience and expertise to her new role. She has been with CIRM since 2012, serving as the Vice President of Therapeutics and Strategic Infrastructure. During her tenure, she has played a crucial role in advancing the field of regenerative medicine and overseeing the development of numerous groundbreaking therapies.<\/p>\n
As the interim CEO, Dr. Millan will be responsible for leading CIRM’s efforts in funding and supporting stem cell research and therapies in California. She will work closely with the CIRM Board of Directors to ensure the organization continues to fulfill its mission of accelerating stem cell treatments to patients with unmet medical needs.<\/p>\n
CIRM is a state agency that was established in 2004 with the passage of Proposition 71, also known as the California Stem Cell Research and Cures Initiative. The agency was created to fund stem cell research and provide grants to scientists and institutions working on regenerative medicine projects.<\/p>\n
Since its inception, CIRM has made significant contributions to the field of regenerative medicine. It has funded over 1,000 projects, ranging from basic research to clinical trials, and has played a pivotal role in advancing stem cell therapies for a wide range of diseases and conditions.<\/p>\n
Under Dr. Millan’s leadership, CIRM will continue to support innovative research and development in regenerative medicine. The organization aims to accelerate the translation of scientific discoveries into clinical applications, ultimately bringing new treatments to patients in need.<\/p>\n
One of the key priorities for CIRM moving forward is to ensure that stem cell therapies are accessible and affordable to all patients. Dr. Millan has expressed her commitment to addressing this issue and working towards equitable access to these life-saving treatments.<\/p>\n
In addition to her role at CIRM, Dr. Millan is a respected leader in the field of regenerative medicine. She has served on various advisory boards and committees, including the International Society for Stem Cell Research and the Alliance for Regenerative Medicine. Her expertise and insights will undoubtedly contribute to the continued success of CIRM.<\/p>\n
The appointment of Dr. Millan as interim CEO has been met with enthusiasm and support from the scientific community. Her extensive knowledge, dedication, and passion for advancing regenerative medicine make her an ideal candidate to lead CIRM during this transitional period.<\/p>\n
As CIRM embarks on a new chapter under Dr. Millan’s leadership, the organization remains committed to its mission of accelerating stem cell therapies and improving the lives of patients. With her guidance, CIRM will continue to be at the forefront of regenerative medicine research and development, bringing hope and healing to countless individuals in California and beyond.<\/p>\n
CIRM Reveals Appointment of Interim CEO The California Institute for Regenerative Medicine (CIRM) has recently announced the appointment of Dr. Maria T. Millan as its interim CEO. This decision comes after the departure of the previous CEO, Dr. C. Randal Mills, who served in the position for nearly seven years. Dr. Millan brings a wealth […]<\/p>\n","protected":false},"author":2,"featured_media":2594906,"menu_order":0,"template":"Default","format":"standard","meta":[],"aiwire-tag":[4299,2012,1892,560,523,314,4250,1976,2049,524,439,440,562,1573,11,441,1978,17,31242,132,18,343,134,9576,20,21,790,4660,23,368,1161,18793,3468,5307,6399,793,2013,5992,6371,2905,966,13217,2000,9457,1396,970,971,3186,972,1398,652,2714,37,975,150,1182,12239,9021,1324,863,591,985,6409,867,5319,6716,9709,1745,997,1198,13925,235,6372,13972,739,163,1788,463,3233,381,50,9079,1016,51,4871,1625,4873,52,31239,31240,11978,29356,5323,5565,2474,8664,1026,1637,1421,1031,4522,1800,57,4326,389,290,1933,1232,1427,3261,6673,2594,608,6350,2358,477,60,885,61,62,1041,887,541,249,3415,692,1901,3109,291,22647,1341,394,67,178,614,1061,396,8550,2097,6013,2601,1530,298,3112,73,179,3179,75,78,183,185,10798,8479,2606,8555,546,8351,5,10,7,31241,8,3430,2502,623,1754,3287,701,3074,85,4232,190,191,6258,356,23279,93,1361,12252,3838,492,8521,3156,496,6217,8561,2518,2618,99,1701,1117,1993,9872,3888,101,639,1760,10975,108,109,3081,2384,2007,9997,207,31464,111,1468,784,11802,3318,9487,116,2302,11017,1136,1997,3324,3325,31466,4185,9,311,2769,7170,124,125,1305,341,126,3019,6],"aiwire":[31029],"_links":{"self":[{"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/platowire\/2594905"}],"collection":[{"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/platowire"}],"about":[{"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/types\/platowire"}],"author":[{"embeddable":true,"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/users\/2"}],"version-history":[{"count":0,"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/platowire\/2594905\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/media\/2594906"}],"wp:attachment":[{"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/media?parent=2594905"}],"wp:term":[{"taxonomy":"aiwire-tag","embeddable":true,"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/aiwire-tag?post=2594905"},{"taxonomy":"aiwire","embeddable":true,"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/aiwire?post=2594905"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}